ArticleCancer research2017
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Protein Arginine Methyltransferases in γ-Globin Regulation and Sickle Cell Disease: Emerging Connections to Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Arginine methylation in cancer: mechanisms and therapeutic implications.Biomarker research · 2025Review
- Identification and targeting of regulators of SARS-CoV-2-host interactions in the airway epithelium.Science advances · 2025Article
- PRMT1 in human neoplasm: cancer biology and potential therapeutic target.Cell communication and signaling : CCS · 2024Review
- A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.Nature communications · 2023Article
- PRMT1 and PRMT5: on the road of homologous recombination and non-homologous end joining.Genome instability & disease · 2023Article
- Elucidating the role of PRMTs in prostate cancer using open access databases and a patient cohort dataset.Histology and histopathology · 2023Article
- TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation.Cell death & disease · 2022Article
- A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer.Cell reports · 2022Article
- How Protein Methylation Regulates Steroid Receptor Function.Endocrine reviews · 2022Review
- Coordinated regulation of the ribosome and proteasome by PRMT1 in the maintenance of neural stemness in cancer cells and neural stem cells.The Journal of biological chemistry · 2021Article
- Structure, Activity, and Function of PRMT1.Life (Basel, Switzerland) · 2021Review
- PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.Journal of personalized medicine · 2021Article
- PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.Nature communications · 2021Article
- Oxidative Stress-A Key Player in the Course of Alcohol-Related Liver Disease.Journal of clinical medicine · 2021Review
- Protein arginine methylation: from enigmatic functions to therapeutic targeting.Nature reviews. Drug discovery · 2021Review
- CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing β-catenin.Oncogene · 2021Article
- Histone methyltransferase and drug resistance in cancers.Journal of experimental & clinical cancer research : CR · 2020Review
- Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response.Nature communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Jessie Hao-Ru HsuDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Benjamin Hubbell-EnglerDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Guillaume AdelmantDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Jialiang HuangDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Cailin E JoyceDepartment of Cancer Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Francisca VazquezThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Barbara A WeirThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Philip MontgomeryThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Aviad TsherniakThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Andrew O GiacomelliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jennifer A PerryDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Jennifer TrowbridgeThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine.
Yuko FujiwaraDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Glenn S CowleyThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Huafeng XieDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Woojin KimDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
Carl D NovinaDepartment of Cancer Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts.
William C HahnThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Jarrod A MartoDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Stuart H OrkinDivision of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts. Stuart_Orkin@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USHoward Hughes Medical Institute · USJackson Laboratory · US
Funding
Systems Analysis of Cancer Pathways in Mouse ModelsU01CA105423 · NCI · DANA-FARBER CANCER INSTITUTE · PI ORKIN, STUART H · 2004 to 2013
$8.4MPROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MSystematic identification of oncogenic KRAS synthetic lethal interactionsU01CA199253 · NCI · BROAD INSTITUTE, INC. · PI HAHN, WILLIAM C. · 2015 to 2019
$3.7MHoward Hughes Medical InstituteNCI NIH HHS P01 CA203655NCI NIH HHS U01 CA105423NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA199253
Abstract
Through an shRNA screen, we identified the protein arginine methyltransferase Prmt1 as a vulnerable intervention point in murine p53/Rb-null osteosarcomas, the human counterpart of which lacks effective therapeutic options. Depletion of Prmt1 in p53-deficient cells impaired tumor initiation and maintenance
Indexed as
Protein BiosynthesisAnimalsBone NeoplasmsDNA MethylationGene Expression Regulation, NeoplasticMiceMice, KnockoutOsteosarcomaProtein-Arginine N-MethyltransferasesProteomicsRetinoblastoma ProteinTumor Cells, CulturedTumor Suppressor Protein p53Xenograft Model Antitumor AssaysPrmt1 protein, mouseProtein-Arginine N-MethyltransferasesRetinoblastoma ProteinTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.